Ivy Union Publishing | http: //www.ivyunion.org January 26, 2015 | Volume 4 | Issue 1 Danish Q et al. American Journals of Cancer Science 2015, 4:1-13 Page 1 of 13 Angiogenesis in Control and Progression of Lung Cancer Qazi Danish, Taseem A. Mokhdomi, Shoiab Bukhari and Raies Ahmad Qadri* Department of Biotechnology, University of Kashmir, Srinagar, J&K, India Introduction Pro-angiogenic endothelial cell signal transduction has evolved as a target of choice in cancer research being indispensable for neovascularization and hence survival of solid tumors [1]. Tumor cells express several target features associated with their angiogenic activation that could be explored as specific targets which may cause either the destruction of existing tumor vasculature [2-5] or inhibition of the tumor angiogenesis [6-8]. Lung tissues are highly vascularised and therefore targeting tumor vessels for destruction may not be a viable option. Therefore, the next strategy may involve use of angiogenic or cell cycle inhibitors or quenchers to restrict neovascularisation and circumvent tumor growth. Although, these will be required in both scenarios, knowledge of the endothelial cell-specific growth factor receptors, their signal transduction and effector mechanisms are essential and will undoubtedly provide essential details to target or restrict human cancers. Here we discuss recent developments on one important family of endothelial growth factor receptors i.e. VEGF receptor family, implicated in lung Review Article American Journals of Cancer Science http://ivyunion.org/index.php/ajcs/ Vol 4 Article ID 201400550, 13 pages Keywords: Lung cancer; Angiogenesis; VEGF receptors Reviewer: Xiying Shang, MD, PhD, UC San Diego Moores Cancer Center, United States Academic Editor: Xiaoning Peng, Hunan Normal University School of Medicine, China Received: October 25, 2014; Accepted: January 20, 2015; Published: January 26, 2015 Competing Interests: The authors have declared that no competing interests exist. Copyright: 2015 Qazi D et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. *Correspondence to: Raies Ahmad Qadri, Department of Biotechnology, University of Kashmir, Srinagar, J&K, India E-mail: raiesamar@yahoo.com Abstract Lung cancer is the major cause of cancer-related mortality worldwide owing to its late-stage detection and aggressive behavior. Epidemiologically, several genetic and epigenetic factors contribute to the development of lung cancer. Angiogenesis, a critical process in tumor progression has become an important target for anti-cancer therapy particularly in lung cancer. Besides commercially available angiogenic inhibitors, numerous anti-angiogenic therapies have been developed to limit tumor growth, although, most of them have not proved beneficial in terms of long-term survival. Despite, logical advances in treatment strategies, NSCLC still remains a major health concern due to poor prognosis of the diseases state. This calls for a comprehensive analysis of signaling processes governing tumor angiogenesis and treatment options available thereof for development of a sustainable strategy to control cancer. In this review, several aspects of lung cancer have been discussed starting from its pathological characterization to the development of modern therapeutics. American Journal of Cancer Science